Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)
Clinical trial NCT05200481 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05200481
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-18
- Primary completion
- 2025-09-01
- Enrollment
- 110
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.